SpringerLink
Log in

Evaluation of Hypertension as a Marker of Bevacizumab Efficacy

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Predictive factors for efficacy of vascular endothelial growth factor pathway-targeted therapies have not been identified or confirmed. Hypertension has been observed as a side effect to anti-vascular endothelial growth factor therapy. The goal of our study was to retrospectively assess if hypertension induced during treatment with bevacizumab was associated with clinical outcome in metastatic colorectal cancer patients treated with bevacizumab.

Patients and methods

We conducted a retrospective chart review of patients with colorectal cancer treated with bevacizumab at Lombardi Comprehensive Cancer Center from 2004 to 2008.

Results

Eighty-four patients with metastatic colorectal cancer were eligible. Eighteen patients (21%) developed grades 3 hypertension. Twelve patients (14%) developed grade 2 hypertension. Six patients (7%) developed grade 1 hypertension. Median overall survival (OS) was 29 months and progression-free survival (PFS) was 10 months. Patients with any grade hypertension while on bevacizumab had an adjusted hazard ratio for death of 0.32 (p = 0.03) and adjusted risk of progression of 51% (p = 0.02) compared to those without hypertension (HTN). When stratified by metastatic disease, patients presenting with metastases who developed HTN had better OS and PFS (p = 0.03 and 0.01.) Among patients without metastases at diagnosis, those with HTN on bevacizumab had better OS and PFS but results were not statistically significant (p = 0.60 and 0.62, respectively).

Conclusions

Our data indicate that bevacizumab-induced hypertension may represent an interesting prognostic factor for clinical outcome in advanced colorectal cancer patients receiving bevacizumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  CAS  PubMed  Google Scholar 

  2. Fuchs CS, Marshall J, Mitchell E, et al. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779–86.

    Article  CAS  PubMed  Google Scholar 

  3. Hochester HS, Hart LL, Ramanathan K, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–9.

    Article  CAS  Google Scholar 

  4. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  CAS  PubMed  Google Scholar 

  5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.

    Article  CAS  PubMed  Google Scholar 

  6. Giantonio BJ, Catalano PJ, Meropol N, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

    Article  CAS  PubMed  Google Scholar 

  7. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–9.

    Article  CAS  PubMed  Google Scholar 

  8. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217–27.

    Article  CAS  PubMed  Google Scholar 

  9. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186–93.

    Article  CAS  PubMed  Google Scholar 

  10. Annex HTD, BH McKendall GR, et al. The viva trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359–65.

    Article  PubMed  CAS  Google Scholar 

  11. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779–803.

    Article  CAS  PubMed  Google Scholar 

  12. Veronese ML, Flaherty KT, Townsend R, et al. Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: mechanisms of hypertension. J Clin Oncol. 2004;14(22 Suppl):2035.

    Google Scholar 

  13. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arterioscler Thromb Vasc Biol. 1997;17:2793–800.

    CAS  PubMed  Google Scholar 

  14. Hood JD, Meininger CJ, Ziche M, Grander HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol. 1998;274:H1054–H58.

    CAS  Google Scholar 

  15. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role of microcirculation. Ann Oncol. 2008;19:927–34.

    Article  PubMed  Google Scholar 

  16. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–30.

    Article  CAS  PubMed  Google Scholar 

  17. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20:393–4.

    Article  CAS  PubMed  Google Scholar 

  18. Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: A multinational, randomized, double-blinded phase III study in 2nd line patients with metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo. J Clin Oncol. 2007;18(25 Suppl):4033.

    Google Scholar 

  19. Miller KD, Chap LI, Holmes F, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–9.

    Article  CAS  PubMed  Google Scholar 

  20. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2005;16(23 Suppl):2.

    Google Scholar 

  21. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol. 2005;16(23 Suppl):3.

    Google Scholar 

  22. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRite). J Clin Oncol. 2006;18(24 Suppl):3537.

    Google Scholar 

  23. Berry S, Cunningham D, Michael M, et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for metastatic colorectal cancer—first B E A trial. J Clin Oncol. 2006;18(24 Suppl):3534.

    Google Scholar 

  24. Agero AL Dusza SW, Benvenuto-Adrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Amer Acad Dermatol. 2006;55:657–70.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Georgetown University Hospital, 3800 Reservoir Rd., Washington, DC, 20007, USA

    Rebekah Ryanne Wu

  2. Department of Oncology, Walter Reed Army Hospital, Washington, DC, USA

    Peter A. Lindenberg

  3. Department of Biostatistics, Bioinformatics, and Biomathematics and Lombardi Comprehensive Cancer Center, Georgetown University, Georgetown, USA

    Rebecca Slack & Anne-Michelle Noone

  4. Department of Medicine and Oncology Lombardi Comprehensive Cancer Center, Georgetown University, Georgetown, USA

    John L. Marshall & Aiwu R. He

Authors
  1. Rebekah Ryanne Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter A. Lindenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebecca Slack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne-Michelle Noone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John L. Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aiwu R. He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebekah Ryanne Wu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ryanne Wu, R., Lindenberg, P.A., Slack, R. et al. Evaluation of Hypertension as a Marker of Bevacizumab Efficacy. J Gastrointest Canc 40, 101–108 (2009). https://doi.org/10.1007/s12029-009-9104-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-009-9104-9

Keywords

Search

Navigation